David H. Aggen, Ph.D.
Affiliations: | 2010 | University of Illinois, Urbana-Champaign, Urbana-Champaign, IL |
Area:
Biochemistry, Immunology, Molecular BiologyGoogle:
"David Aggen"Mean distance: (not calculated yet)
Parents
Sign in to add mentorDavid Michael Kranz | grad student | 2010 | UIUC | |
(Engineering human single-chain T cell receptors.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Aggen DH, Rosenberg JE. (2024) Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma. Nature Reviews. Clinical Oncology |
Dallos M, Aggen DH, Hawley J, et al. (2019) A randomized phase Ib/II study of nivolumab with or without BMS-986253 in combination with a short course of ADT in men with castration-sensitive prostate cancer (MAGIC-8). Journal of Clinical Oncology. 37: TPS329-TPS329 |
Aggen DH, Ghasemzadeh A, Mao W, et al. (2019) Preclinical development of combination therapy targeting the dominant cytokine interleukin-1β for renal cell carcinoma. Journal of Clinical Oncology. 37: e14237-e14237 |
Dallos M, Obradovic A, Chowdhury N, et al. (2019) Human prostate cancer immune phenotypes after androgen deprivation therapy. Journal of Clinical Oncology. 37: 5083-5083 |
Chowdhury N, Obradovic A, Aggen D, et al. (2019) Abstract 1476: Decoding the immunologic landscape of human clear cell renal carcinoma Cancer Research. 79: 1476-1476 |
Wang* V, Obradovic A, Chowdhury N, et al. (2019) MP21-01 SINGLE CELL TRANSCRIPTIONAL PROFILING OF IMMUNE POPULATIONS WITHIN RENAL CELL CARCINOMA TUMOR MICROENVIRONMENT Journal of Urology. 201 |
Schmitt TM, Aggen DH, Ishida-Tsubota K, et al. (2017) Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro. Nature Biotechnology |
Stone JD, Harris DT, Soto CM, et al. (2014) A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. Cancer Immunology, Immunotherapy : Cii. 63: 1163-76 |
Schmitt TM, Aggen DH, Stromnes IM, et al. (2013) Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood. 122: 348-56 |
Schmitt TM, Greenberg PD, Aggen DH, et al. (2013) Abstract PR12: Early TCRα expression during T cell development for the generation of enhanced-affinity TCRs for TCR gene therapy. Cancer Research. 73 |